Skip to main content
. 2018 Apr 10;84(6):1335–1345. doi: 10.1111/bcp.13565

Figure 2.

Figure 2

Comparison of observed and predicted plasma concentration–time profiles of BMS‐823778 following a single and multiple oral doses to healthy Chinese subjects with (A) CYP2C19 extensive metabolizers (15 mg); (B) CYP2C19 intermediate metabolizers (15 mg); (C) CYP2C19 poor metabolizers (15 mg). Observed data: open circles; mean simulated profile: black line; individual simulated profile: grey line